This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

31 Mar 2012

GenSpera Moves to Phase-Ib Stage of G-202 Development

GenSpera's lead product G-202 will now be evaluated in a phase-Ib trial following successful dose-escalation studies.

GenSpera is continuing clinical development of its lead chemotherapeutic agent G-202 after successfully completing dose-escalation studies.


The drug candidate will now progress to phase-Ib development, during which it will be evaluated in up to 18 additional patients in order to refine the dosing regimen and determine the dose to be used in subsequent phase-II clinical trials.


A phase-II trial involving patients with castrate-resistant, chemotherapy-naive prostate cancer is expected to commence within the next few months.


Dr Craig Dionne, the development-stage oncology company's chief executive officer, said: "This is a critical step in the GenSpera clinical programme and is a major validation

Related News